Literature DB >> 29260621

Immunologic treatment of Parkinson's disease.

Joseph Jankovic1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29260621     DOI： 10.2217/imt-2017-0146

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  3 in total

1.  Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Authors:  Joseph Jankovic; Ira Goodman; Beth Safirstein; Tonya K Marmon; Dale B Schenk; Martin Koller; Wagner Zago; Daniel K Ness; Sue G Griffith; Michael Grundman; Jay Soto; Susanne Ostrowitzki; Frank G Boess; Meret Martin-Facklam; Joseph F Quinn; Stuart H Isaacson; Omid Omidvar; Aaron Ellenbogen; Gene G Kinney
Journal:  JAMA Neurol       Date:  2018-10-01       Impact factor: 18.302

Review 2.  Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight.

Authors:  Matthew Upcott; Kirill D Chaprov; Vladimir L Buchman
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

Review 3.  An early diagnosis is not the same as a timely diagnosis of Parkinson's disease.

Authors:  Richard Nathaniel Rees; Anita Prema Acharya; Anette Schrag; Alastair John Noyce
Journal:  F1000Res       Date:  2018-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.